GW Pharmaceuticals Announces Appointment of Julian Gangolli to Board of Directors

GW Pharmaceuticals Announces Appointment of Julian Gangolli to Board of Directors

London, UK, 21 July 2015: GW Pharmaceuticals plc (Nasdaq: GWPH, AIM: GWP, "GW," "the Company" or "the Group"), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, announced that the Company has appointed Julian Gangolli to the Board of Directors effective immediately. This follows the announcement on 19 May 2015 of Mr Gangolli's appointment to the newly created position of President, North America.

"I am delighted to welcome Julian to the GW board of directors as he brings exceptional operational and leadership experience to the group," stated GW's Chairman Dr. Geoffrey Guy. "As we advance our commercial plans for Epidiolex, it is of significant value for the Board to tap into the perspective of such an experienced business leader that has extensive product commercialization experience and a successful track record of launching and growing specialty pharmaceutical products in the U.S."

Mr. Gangolli, was, from 2004 until April 2015, President of the North American Pharmaceutical division of Allergan Inc, with responsibility for a 1,400-person integrated commercial operation with sales exceeding $3.8 billion in 2014. As a Corporate Vice President and member of the Executive Committee, Allergan's most senior leadership team overseeing worldwide operations, Mr. Gangolli was an integral part of the executive management team that transformed Allergan into one of the leading specialty pharmaceutical companies in the U.S. Prior to Allergan, Mr. Gangolli was Vice President, Sales and Marketing at VIVUS, Inc. where he established from inception a fully functioning commercial operation. Prior to VIVUS, Mr. Gangolli held roles at Syntex Pharmaceuticals, Inc. and Ortho-Cilag Pharmaceuticals Ltd. in the UK. He was raised and educated in the UK and is a U.S. citizen.

About GW Pharmaceuticals plc

Founded in 1998, GW is a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform in a broad range of disease areas. GW commercialized the world's first plant-derived cannabinoid prescription drug, Sativex®, which is approved for the treatment of spasticity due to multiple sclerosis in 27 countries outside the United States. GW is advancing an orphan drug program in the field of childhood epilepsy with a focus on Epidiolex®, which is in Phase 3 clinical development for the treatment of Dravet syndrome and Lennox-Gastaut syndrome and which is also expected to enter Phase 3 clinical trials in the treatment of Tuberous Sclerosis Complex. GW has a deep pipeline of additional cannabinoid product candidates which includes Sativex in Phase 3 clinical development as a potential treatment of pain associated with advanced cancer, as well as compounds in Phase 1 and 2 trials for glioma, type 2 diabetes, and schizophrenia. For further information, please visit www.gwpharm.com.

GW Pharmaceuticals plc

(Today) +44 20 3727 1000

Stephen Schultz, VP Investor Relations (U.S.)

917 280 2424 / 401 500 6570

FTI Consulting (Media Enquiries)

Ben Atwell / Simon Conway / John Dineen (UK)

• 44 20 3727 1000

Robert Stanislaro (U.S.)

212 850 5657

Trout Group, LLC (U.S. investor relations)

Todd James / Chad Rubin

646 378 2900